How artificial intelligence can boost computer-aided drug design in ESKAPE infections

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d6254358e156">Computer-aided drug design (CADD) is a key approach in drug discovery, playing a crucial role in the development of many approved drugs. The integration of artificial intelligence (AI), driven by the increasing availability of data and continuous model refinement, is creating new opportunities for predicting target structures, drug interactions, molecular properties, novel molecules, and drug repurposing [1]. In this study, we demonstrate how combining physics-based and deep-learning approaches in CADD can help redirect existing drugs to combat ESKAPE infections. The World Health Organization has identified antimicrobial resistance as a major global threat, with ESKAPE pathogens, six highly drug-resistant bacteria, being a leading cause of hospital-acquired infections [2]. Among them, the most concerning are the highly resistant Gram-negative bacteria Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, which pose a serious risk, particularly to critically ill patients. Our research focuses on the LpxM lipid A acyltransferase protein from A. baumannii, which reinforces the bacterium's membrane, increasing its virulence and enhancing infection and transmission rates [3]. Due to its critical role, LpxM is an attractive target for new antimicrobial drugs. To identify potential inhibitors, we performed virtual screening and molecular dynamics simulations using the "World" subset of the ZINC database, which includes drugs approved in major global jurisdictions, along with the crystal structure of LpxM. The top-ranking candidate drugs, based on calculated binding energies, are being selected for experimental evaluation of their effects on enzymatic activity and bacterial fitness. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d6254358e158"/><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d6254358e159">[1] Pirolli et al. (2023) Sci Rep 13:1494 <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d6254358e161">[2] Mulani et al. (2019) Front Microbiol 10: 539. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d6254358e163">[3] Boll et al. (2015) mBio 6(3): e00478-00415

Authors

Institutions

Publication Details

Published
2025-04-12
DOI
https://doi.org/10.14293/idr.25.009mc
Primary Topic
vaccines and immunoinformatics approaches
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

How artificial intelligence can boost computer-aided drug design in ESKAPE infections

Alessandro Semeraro, Flavia Squeglia, Benedetta Righino, Davide Pirolli et al.
vaccines and immunoinformatics approaches
article

How artificial intelligence can boost computer-aided drug design in ESKAPE infections

Alessandro Semeraro, Flavia Squeglia, Benedetta Righino, Davide Pirolli, Maria Cristina De Rosa, Juan José Galano-Frutos, Beatrice Scagnoli
article en

Abstract

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d6254358e156">Computer-aided drug design (CADD) is a key approach in drug discovery, playing a crucial role in the development of many approved drugs. The integration of artificial intelligence (AI), driven by the increasing availability of data and continuous model refinement, is creating new opportunities for predicting target structures, drug interactions, molecular properties, novel molecules, and drug repurposing [1]. In this study, we demonstrate how combining physics-based and deep-learning approaches in CADD can help redirect existing drugs to combat ESKAPE infections. The World Health Organization has identified antimicrobial resistance as a major global threat, with ESKAPE pathogens, six highly drug-resistant bacteria, being a leading cause of hospital-acquired infections [2]. Among them, the most concerning are the highly resistant Gram-negative bacteria Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, which pose a serious risk, particularly to critically ill patients. Our research focuses on the LpxM lipid A acyltransferase protein from A. baumannii, which reinforces the bacterium's membrane, increasing its virulence and enhancing infection and transmission rates [3]. Due to its critical role, LpxM is an attractive target for new antimicrobial drugs. To identify potential inhibitors, we performed virtual screening and molecular dynamics simulations using the "World" subset of the ZINC database, which includes drugs approved in major global jurisdictions, along with the crystal structure of LpxM. The top-ranking candidate drugs, based on calculated binding energies, are being selected for experimental evaluation of their effects on enzymatic activity and bacterial fitness. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d6254358e158"/><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d6254358e159">[1] Pirolli et al. (2023) Sci Rep 13:1494 <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d6254358e161">[2] Mulani et al. (2019) Front Microbiol 10: 539. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d6254358e163">[3] Boll et al. (2015) mBio 6(3): e00478-00415

Institute of Biostructure and Bioimaging (IT), Consorzio Roma Ricerche (IT)
Openalex Percentile: Top 93%
vaccines and immunoinformatics approaches
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.